⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
AGARWALEYE - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.8
| Stock Code | AGARWALEYE | Market Cap | 14,141 Cr. | Current Price | 446 ₹ | High / Low | 568 ₹ |
| Stock P/E | 270 | Book Value | 61.8 ₹ | Dividend Yield | 0.00 % | ROCE | 5.94 % |
| ROE | 1.31 % | Face Value | 1.00 ₹ | DMA 50 | 483 ₹ | DMA 200 | 464 ₹ |
| Chg in FII Hold | -0.07 % | Chg in DII Hold | -0.14 % | PAT Qtr | 4.95 Cr. | PAT Prev Qtr | 10.4 Cr. |
| RSI | 32.0 | MACD | -17.7 | Volume | 74,433 | Avg Vol 1Wk | 3,88,762 |
| Low price | 327 ₹ | High price | 568 ₹ | PEG Ratio | 1.77 | Debt to equity | 0.30 |
| 52w Index | 49.5 % | Qtr Profit Var | 512 % | EPS | 1.55 ₹ | Industry PE | 45.3 |
📊 Agarwal Eye Hospital (AGARWALEYE) shows extremely high valuation, weak efficiency ratios, and declining profits. Despite sectoral growth potential, it is a risky candidate for swing trading, suitable only for cautious short-term trades near strong support levels.
✅ Optimal Entry Price: 430–440 ₹ (near 200 DMA support)
🚪 Exit Strategy if Holding: Consider exiting near 470–480 ₹ (short-term resistance zone around 50 DMA) or if RSI moves above 45.
Positive
- 💡 EPS of 1.55 ₹ provides earnings base.
- 📈 Quarterly profit variation (+512%) shows strong year-on-year rebound despite sequential decline.
- 🏦 Debt-to-equity ratio of 0.30 indicates moderate leverage.
- 📊 PEG ratio of 1.77 suggests fair valuation relative to growth compared to peers.
- 📈 52-week index performance (+49.5%) shows strong long-term momentum.
Limitation
- ⚠️ Extremely high P/E (270) compared to industry average (45.3), suggesting severe overvaluation.
- 📉 Weak ROCE (5.94%) and ROE (1.31%) indicate poor efficiency.
- 🔻 RSI at 32.0 signals oversold conditions but also weak momentum.
- 📊 MACD (-17.7) confirms bearish trend.
- 💰 Dividend yield of 0.00% offers no passive income.
Company Negative News
- 📉 Decline in FII holdings (-0.07%) and DII holdings (-0.14%) shows reduced institutional confidence.
- 📊 PAT dropped from 10.4 Cr. to 4.95 Cr., highlighting earnings weakness.
Company Positive News
- 📈 Strong year-on-year profit variation (+512%) highlights operational recovery.
- 📊 PEG ratio indicates valuation is not entirely unreasonable relative to growth.
Industry
- 🏭 Industry P/E at 45.3 is far lower than AGARWALEYE’s 270, highlighting extreme premium valuation.
- 📈 Healthcare and specialty hospitals sector remains in demand, supported by rising medical needs and urban healthcare expansion.
Conclusion
🔎 Agarwal Eye Hospital is fundamentally overvalued and technically weak, despite strong year-on-year profit growth. Swing traders may cautiously enter near 430–440 ₹ and exit near 470–480 ₹. Monitoring RSI and MACD is crucial, as momentum indicators suggest limited upside unless a reversal occurs.